Protocol Ledger

NCT04846491 · Phase III · COMPLETED

A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B

Interventional Phase III clinical trial protocol NCT04846491 sponsored by Xiamen Amoytop Biotech Co in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-12-04 Enrollment: 475 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04846491
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)475 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04846491
Protocol FieldVerified Registry Value
NCT IdentifierNCT04846491
Consolidated Lead SponsorXiamen Amoytop Biotech Co
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment475 participants (ACTUAL)
Registered Start Date2019-12-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI